Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc. - Common Stock
(NQ:
BEAM
)
28.31
-0.98 (-3.35%)
Streaming Delayed Price
Updated: 9:42 AM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
June 13, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab
↗
June 11, 2025
Via
Benzinga
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
June 03, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Analyst Expectations For Beam Therapeutics's Future
↗
February 27, 2025
Via
Benzinga
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 29, 2025
From
Beam Therapeutics
Via
GlobeNewswire
BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
May 23, 2025
Via
Investor Brand Network
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
May 14, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
May 13, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 12, 2025
From
Beam Therapeutics
Via
GlobeNewswire
10 Analysts Assess Beam Therapeutics: What You Need To Know
↗
May 07, 2025
Via
Benzinga
Why Beam Therapeutics Stock Tanked on Tuesday
↗
May 06, 2025
Via
The Motley Fool
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 06, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
↗
April 21, 2025
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Via
Investor's Business Daily
Topics
Government
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
↗
April 21, 2025
Via
Benzinga
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
↗
April 07, 2025
Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND
Via
Benzinga
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
April 05, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
↗
April 04, 2025
Via
Benzinga
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'
↗
April 04, 2025
Via
Benzinga
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
↗
March 28, 2025
Via
Benzinga
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
↗
March 28, 2025
Via
Benzinga
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
March 27, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
↗
March 22, 2025
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.
Via
Benzinga
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
↗
March 10, 2025
Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.
Via
Benzinga
Beam Therapeutics Announces Pricing of Underwritten Offering
March 10, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
March 10, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%
↗
March 04, 2025
Via
Benzinga
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
February 25, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
February 24, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
↗
February 22, 2025
Via
Benzinga
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
↗
February 15, 2025
Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
